Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biora Therapeutics, Inc. - Common Stock
(NQ:
BIOR
)
0.5040
-0.0303 (-5.67%)
Streaming Delayed Price
Updated: 1:41 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biora Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Biora Therapeutics Achieves ISO 13485 Certification
September 09, 2024
Underscoring the company’s commitment to quality and excellence
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Positive Nasdaq Listing Decision
August 28, 2024
Company granted extension to regain compliance with Nasdaq listing requirements
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
August 26, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 12, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Funding Agreement with Existing Investors
August 12, 2024
$16 million multiple-draw facility to be used as a bridge to anticipated pharma partnership
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
August 08, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
August 06, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
July 18, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
July 08, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
July 01, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
June 11, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
May 20, 2024
Four clinical device performance studies successfully demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions and eating schedules
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 15, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
May 07, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
May 06, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
April 30, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
April 08, 2024
Claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
April 04, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 03, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 01, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
March 26, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
March 18, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
March 11, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
February 26, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
February 08, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
January 22, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Provides Outlook for 2024
January 16, 2024
Multiple catalysts anticipated in 2024, including clinical study results for NaviCap™ Targeted Oral Delivery Platform and progress on pharma partnerships for BioJet™ Systemic Oral Delivery Platform
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
January 08, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
January 02, 2024
BioJet device exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical study
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
December 19, 2023
Patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tract
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.